EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-World Outcomes and Prognostic Factors in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Sorafenib: A Multicenter Study

Suheda Atas Ipek iD, Sendag Yaslikaya iD, Ismail Oguz Kara, Tolga Koseci, Ertugrul Bayram iD, Esra Asarkaya, Hatice Asoglu iD, Mehmet Turker iD, Abdurrahman Aykut iD, Seda Jeral Evinc iD, Ozkan Alan iD, Mehmet Emin Yilmaz iD und 24 weitere

Journal of Clinical Medicine · 23.06.2026 · 15 (13) · 4880

DOI: 10.3390/jcm15134880 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 23.06.2026. Verfasst von Suheda Atas Ipek und 35 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Faculty of Medicine, Cukurova University, Adana 01330, Turkey. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sorafenib remains an important treatment option for patients with radioiodine-refractory differentiated thyroid cancer (RAI-R DTC). This study evaluated real-world outcomes and prognostic factors in patients treated with sorafenib. Materials and Methods: This retrospective multicenter study included 176 patients with RAI-R DTC treated with sorafenib between 2000 and 2024 across sixteen centers. Clinical, pathological and treatment-related variables, including metastatic sites, radiotherapy, dose reduction, inflammatory markers (neutrophil-to-lymphocyte ratio [NLR] and platelet-to-lymphocyte ratio [PLR]) and pretreatment thyroglobulin (Tg), were analyzed. Progression-free survival (PFS) was evaluated using Kaplan–Meier analysis. Prognostic factors were assessed using univariate and multivariate Cox regression analyses.

Results

The median follow-up duration was 24 months and the median PFS was 21 months (95% CI: 15.5–26.5). Partial response was observed in 82 patients (46.6%), stable disease in 55 (31.3%) and progressive disease in 35 (19.9%). Patients who underwent dose reduction had longer PFS than those without dose reduction (42 vs. 19 months, p = 0.030), and absence of dose reduction remained independently associated with progression risk. Patients who received radiotherapy had shorter PFS than those who did not receive radiotherapy (16 vs. 37 months, p = 0.002), and radiotherapy-related variables remained independent predictors of progression. Patients with PLR values >138.2 had shorter PFS than those with PLR values ≤ 138.2 (19 vs. 34 months, p = 0.047), although this association was not maintained in Cox regression analysis. Similarly, associations between NLR and Tg values and PFS did not reach statistical significance (p = 0.112 and p = 0.072, respectively). Hand–foot syndrome was the most common toxicity, occurring in 59 patients (33.5%), while Grade 3 hand–foot syndrome was observed in 7 patients (4.0%).

Conclusions

Sorafenib provided meaningful disease control with a median PFS of 21 months in this real-world cohort. Dose reduction was associated with longer PFS, whereas radiotherapy requirement appeared to reflect a higher-risk subgroup. Toxicities were generally manageable.

Schlagwörter

Stichwörter der Autor:innen

PLRRAI-R DTCdose reductionprogression-free survivalradiotherapysorafenib

Autor:innen und Institutionen

  • Department of Medical Oncology, Faculty of Medicine, Cukurova University, Adana 01330, Turkey.
  • Department of Medical Oncology, Giresun Training and Research Hospital, Giresun 28200, Turkey.
  • Department of Medical Oncology, Adana Training and Research Hospital, Adana 01370, Turkey.
  • Department of Medical Oncology, Cerrahpasa Faculty of Medicine, Istanbul 34098, Turkey.
  • Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara 06200, Turkey.
  • Department of Medical Oncology, Faculty of Medicine, Ankara University, Ankara 06590, Turkey.

ORCID-Profile: Suheda Atas Ipek, Sendag Yaslikaya, Ertugrul Bayram, Hatice Asoglu, Mehmet Turker, Abdurrahman Aykut, Seda Jeral Evinc, Ozkan Alan, Mehmet Emin Yilmaz, Hatime Arzu Yasar, Mehmet Kayaalp, Esra Asik, Atila Yildirim, Burcu Bacak, Meltem Baykara, Muhammed Bekir Hacioglu, Ferhat Ekinci, Ahmet Burak Agaoglu, Mesut Yilmaz, Sedat Biter, Mehmet Mutlu Kıdı, Yasemin Aydınalp Camadan, Mahmut Buyuksimsek

Zitieren

APA

Atas Ipek, S., Yaslikaya, S., Kara, I. O., Koseci, T., Bayram, E., Asarkaya, E., Asoglu, H., Turker, M., Aykut, A., Jeral Evinc, S., Alan, O., Yilmaz, M. E., Ates, O., Yasar, H. A., Kayaalp, M., Asik, E., Yildirim, A., Bacak, B., Baykara, M., …, & Buyuksimsek, M. (2026). Real-World Outcomes and Prognostic Factors in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Sorafenib: A Multicenter Study. Journal of Clinical Medicine, 15(13), 4880. https://doi.org/10.3390/jcm15134880

Vancouver

Atas Ipek S, Yaslikaya S, Kara IO, Koseci T, Bayram E, Asarkaya E, et al. Real-World Outcomes and Prognostic Factors in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Sorafenib: A Multicenter Study. Journal of Clinical Medicine. 2026;15(13):4880. doi:10.3390/jcm15134880

BibTeX
@article{AtasIpek2026,
  author = {Atas Ipek, Suheda and Yaslikaya, Sendag and Kara, Ismail Oguz and Koseci, Tolga and Bayram, Ertugrul and Asarkaya, Esra and Asoglu, Hatice and Turker, Mehmet and Aykut, Abdurrahman and Jeral Evinc, Seda and Alan, Ozkan and Yilmaz, Mehmet Emin and Ates, Ozturk and Yasar, Hatime Arzu and Kayaalp, Mehmet and Asik, Esra and Yildirim, Atila and Bacak, Burcu and Baykara, Meltem and Yurdatap Koc, Dicle and Hacioglu, Muhammed Bekir and Alkan, Suleyman and Ekinci, Ferhat and Agaoglu, Ahmet Burak and Yilmaz, Mesut and Hacibekiroglu, Ilhan and Karaca, Mustafa and Guclu Kantar, Taliha and Gokoz Dogu, Gamze and Karacelik, Tuba and Eryilmaz, Melek Karakurt and Sakalar, Teoman and Biter, Sedat and Kıdı, Mehmet Mutlu and Aydınalp Camadan, Yasemin and Buyuksimsek, Mahmut},
  title = {Real-World Outcomes and Prognostic Factors in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Sorafenib: A Multicenter Study},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {13},
  pages = {4880},
  doi = {10.3390/jcm15134880}
}
Kostenlos starten →